Difference between revisions of "Alpelisib (Piqray)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://clinicaltrials.gov/ct2/show/[https://clinicaltrials.gov/ct2/show/" to "https://clinicaltrials.gov/ct2/show/") |
Warner-admin (talk | contribs) m (Text replacement - "‑" to "-") |
||
| Line 13: | Line 13: | ||
*2020-07-27: Initial authorization | *2020-07-27: Initial authorization | ||
==History of changes in Health Canada indication== | ==History of changes in Health Canada indication== | ||
| − | *2020-03-11: Initial notice of compliance in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone | + | *2020-03-11: Initial notice of compliance in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic [[breast cancer]] after disease progression following an endocrine-based regimen. |
==Also known as== | ==Also known as== | ||
Revision as of 13:39, 7 June 2023
Mechanism of action
From NCI Drug Dictionary: An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2019-05-24: Approved in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. (Based on Clinical Trial Registry SOLAR-1])
History of changes in EMA indication
- 2020-07-27: Initial authorization
History of changes in Health Canada indication
- 2020-03-11: Initial notice of compliance in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.
Also known as
- Code name: BYL719
- Brand name: Piqray